VitalO₂ Monitor
Early detection of cellular oxygen deficiency (cytopathic hypoxia) in sepsis, trauma, respiratory failure, and cardiac failure
Key Facts
About Opticyte
Opticyte is pioneering a breakthrough in patient monitoring with its VitalO₂ device, which has received FDA Breakthrough Device Designation. The device aims to detect cellular oxygen deficiency (cytopathic hypoxia) in real-time, allowing for earlier intervention in life-threatening conditions such as sepsis, trauma, and respiratory failure. By combining cellular and blood oxygen measurements in a skin-tone unbiased system, Opticyte targets a critical gap in current standard-of-care diagnostics, particularly the well-documented inaccuracies of conventional pulse oximeters in patients with darker skin. The company is positioned to address a massive global healthcare need while advancing health equity.
View full company profile